Migraine Med Shows Weight-Loss Benefit

 Atogepant (Qulipta, AbbVie), an oral, calcitonin gene-related peptide (CGRP) receptor antagonist FDA-approved for the prevention of migraine, may do more than reduce headache frequency — it may also drive meaningful weight loss in patients with overweight or obesity.

In an open-label extension study, nearly one third of patients consistently taking atogepant 60 mg once daily experienced a 5% or greater weight reduction over 1 year of treatment, with about 13% having 10% or greater weight loss.

For weight loss, patients “must take the 60 mg dose and they must take it consistently over time,” said Jessica Ailani, MD, director of the Medstar Georgetown Headache Center, Washington, DC.

The study was presented on April 21 at the American Academy of Neurology (AAN) 2026 Annual Meeting.

Weight Problems Common

Ailani noted that up to 60% of adults with migraine have overweight or obesity, which is associated with increased migraine frequency and severity. A previous analysis of five clinical trials demonstrated that atogepant 60 mg once daily was associated with modest, dose- and duration-dependent weight loss among patients with migraine, irrespective of weight status.

The weight loss potential with atogepant emerged in a post hoc subgroup analysis within a large, ongoing 156-week open-label extension study of the drug.

The analysis focused on 279 adults (mean age, 42 years; 83% women) with episodic and chronic migraine and a BMI ≥ 25 who received at least one dose of atogepant 60 mg daily. Most patients had two or more cardiovascular risk factors.

Outcomes included change in mean weight over time, the proportion of patients achieving ≥ 5% or ≥ 10% weight loss at week 52, and the incidence of weight-related adverse events.

Reductions in body weight with atogepant began early and continued over time, Ailani reported.

“Within the first 4 weeks, participants were starting to have weight loss to the degree of about 2 lb,” Ailani said, describing the pattern that was “steady” and “consistent.”

The trajectory showed incremental reductions in weight across multiple timepoints through week 52. Importantly, the pattern was not strictly linear but cyclical, with periods of plateau followed by further decline — “very similar to what you see with weight loss in general,” Ailani told conference attendees.

By 1 year, 34.9% of participants achieved at least 5% weight reduction, whereas 12.8% achieved at least 10% weight loss. Among those who reached these thresholds, mean reductions were approximately 10 kg (22 lb) and 16.5 kg (36 lb), respectively.

The incidence of weight-related treatment-emergent adverse events was low, with no events leading to treatment discontinuation.

Ailani said it’s not clear why atogepant leads to weight loss, but it doesn’t appear to be explained by gastrointestinal side effects.

“Side effects of nausea or constipation are very transient and didn’t seem to correlate with those patients that actually were experiencing weight loss,” she said.

A Compelling Signal

While the analysis offers a “compelling signal” it should not be “overinterpreted” said Shaheen Lakhan, MD, PhD, neurologist, and researcher based in Miami, who was not involved in the research.

“At present, the clearest weight-loss signal appears to be with atogepant, and we do not yet have comparable long-term data showing the same magnitude consistently across the broader gepant class. For now, I’d view this as an intriguing agent-specific observation rather than a confirmed class effect,” Lakhan told Medscape Medical News.

The signal, he said, is biologically plausible, as CGRP pathways contribute to appetite control, satiety, gastrointestinal signaling, and overall metabolic function. He also said that improvements in migraine symptoms alone may promote weight loss, even without a direct effect from the drug.

He noted that patients with frequent migraine often struggle with exercise consistency, sleep disruption, irregular meals, stress eating, and reduced day-to-day activity. When migraine burden improves, many become more active, sleep better, and re-establish healthier routines.

“That distinction is important because some of the weight signal may reflect pharmacology, while some may simply reflect better functioning from having fewer migraines,” Lakhan said.

There is also a broader body of research connecting migraine and obesity, he added. Obesity has been linked to more frequent migraines and a higher likelihood of developing chronic migraine, while weight loss, whether through lifestyle changes or bariatric surgery — has been associated with fewer headache days, reduced pain intensity, and improved functioning. This suggests the relationship is likely bidirectional.

In his view, what makes these data “noteworthy is the durability of the signal over 1 year and the proportion of patients achieving clinically meaningful weight reduction. Still, this was a post hoc analysis from an open-label extension study, so it should be viewed as hypothesis-generating rather than practice-changing,” said Lakhan.

“Would I consider atogepant in a patient with migraine and obesity? Certainly as a favorable tiebreaker if efficacy, tolerability, access, and comorbidities otherwise align. But I would not choose it solely as a weight-loss strategy at this stage,” Lakhan said.

“The broader takeaway is that successful migraine prevention may carry metabolic benefits, and that is an area deserving much closer study,” he added.

This study was supported by AbbVie. Disclosure information for study authors is available in the original study publication. Lakhan had no relevant disclosures.

https://www.medscape.com/viewarticle/migraine-med-shows-weight-loss-benefit-2026a1000dm5